摘要
分析重组人白介素-11对恶性肿瘤患者化疗后血小板计数平均值的影响及不良反应发生率。利用随机数字表法选取2015年1月~2018年12月于该院接受化疗治疗的100例血小板计数<70×109/L的恶性肿瘤患者分为采取重组人白介素-11治疗的观察组及采取常规治疗的对照组各50例,对两组血小板计数平均值、不良反应发生率进行对比。治疗前两组血小板计数平均值无明显差异,治疗后1,3,7 d两组比较,不同时间点血小板计数平均值差异有统计学意义(P <0. 05),观察组与对照组血小板计数平均值差异无统计学意义(P> 0. 05),两组血小板计数平均值变化趋势无统计学意义(P> 0. 05);两组不良反应发生率数值相当,差异无统计学意义(P> 0. 05)。重组人白介素-11能够有效提升恶性肿瘤患者化疗后血小板计数平均值且不良反应发生率小,建议临床为优选用药。
To analyze the effect of recombinant human interleukin-11( rh IL-11) on the mean platelet count and the incidence of adverse reactions in patients with malignant tumors after chemotherapy;100 randomized patients with malignant tumors with platelet count < 70 × 109/L who received chemotherapy in Wuxi No. 2 people’s hospital from January 2015 to December 2018 were divided into control group and observation group;the observation group were treated with recombinant human interleukin-11. The control group of the conventional treatment group had 50 cases,and the average value of platelet count and incidence of adverse reactions were compared between the two groups. There was no significant difference in the mean platelet count between the two groups before treatment. The mean difference of platelet counts at different time points was statistically significant at 1 day,3 days and 7 days after treatment( P < 0. 05). There was no significant difference in mean platelet counts between the two groups( P > 0. 05). There was no significant difference in the mean platelet count between the two groups( P > 0. 05). The incidence of adverse reactions was similar in the two groups,and the difference was not statistically significant( P > 0. 05). Recombinant human interleukin-11 can effectively increase the mean platelet count of malignant tumor patients after chemotherapy,and the incidence of adverse reactions is small,so it is suggested that it can be used as an optimal drug.
作者
何文婷
乔劲鹏
HE Wen-ting;QIAO Jin-peng(Pharmacy Department,Wuxi No.2 People’s Hospital,Wuxi 214000,China;Oncology Department,Wuxi No.2 People’s Hospital,Wuxi 214000,China)
出处
《药物生物技术》
CAS
2019年第5期416-418,共3页
Pharmaceutical Biotechnology
关键词
恶性肿瘤
化疗
血小板计数
重组人白介素-11
不良反应
浓缩血小板
激素
Malignant tumors
Chemotherapy
Platelet count
Recombinant human interleukin-11
Adverse reactions
Concentrated platelets
Hormones
